Table III.

Dose modification of selected tsDMARD in renal insufficiency [35–37, 39]

tsDMARD	Dose modification in renal insufficiency
Tofacitinib	CrCl ≥ 30 ml/min – NDAR (5 mg twice per day) [35] CrCl < 30 ml/min – reduction of dose by 50% (5 mg once a day) [35]
	Hemodialysis: In patients with severe renal impairment the reduced dose should be maintained even after hemodialysis [35] Peritoneal dialysis: ND CRTT: ND
Baricitinib	CrCl ≥ 60 ml/min – NDAR (4 mg one a day) [37] CrCl 30–< 60 ml/min – reduction of dose by 50% (2 mg once a day) [37] CrCl < 30 ml/min – ND, use is not recommended [37]
	Hemodialysis: ND Peritoneal dialysis: ND CRTT: ND
Upadacitinib	CrCl ≥ 30 ml/min – NDAR [36] CrCl 15–< 30 ml/min – caution should be exercised (15 mg once a day) [36] CrCl < 15 ml/min – ND, use is not recommended [36]
	Hemodialysis: ND Peritoneal dialysis: ND CRTT: ND
Filgotinib	CrCl ≥ 60 ml/min – NDAR (200 mg once a day) [39] CrCl 15–< 60 ml/min – reduction of dose by 50% (100 mg once a day) [39] CrCl < 15 ml/min – ND, use is not recommended [39]
	Hemodialysis: ND Peritoneal dialysis: ND CRTT: ND

CrCl – creatinine clearance, CRTT – continuous renal replacement therapy, DAR – dose adjustment required, ND – no data, NDAR – no dose adjustment required, tsDMARD – targeted synthetic disease-modifying antirheumatic drugs.